Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2025-07-11 00:00:00 ET · period of report 2025-07-09 · accession 0001714899-25-000149 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-07-11 | 2025-07-09 | DNLI | Watts Ryan J. | Pres, CEO, Dir | M - OptEx | $1.05 | +495.3K | 708.4K | +232% | +$520.8K |
| D | 2025-07-11 | 2025-07-09 | DNLI | Watts Ryan J. | Pres, CEO, Dir | S - Sale+OE | $15.00 | -495.3K | 253.1K | -66% | -$7.43M |
| DM | 2025-07-11 | 2025-07-09 | DNLI | Watts Ryan J. | Pres, CEO, Dir | M - OptEx | $0.00 | -495.3K | 20.4K | -96% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-09 | M | A | 40,000 | $5.28 | 748,353 | D | — | — | (F1) Includes 177,940 Unvested RSUs. |
| 2 | Common | Common Stock | 2025-07-09 | S | D | 495,282 | $15.00 | 253,071 | D | — | — | (F3) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $15.00 to $15.08 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F1) Includes 177,940 Unvested RSUs. |
| 3 | Common | Common Stock | 2025-07-09 | M | A | 455,282 | $0.68 | 708,353 | D | — | — | (F1) Includes 177,940 Unvested RSUs. |
| 4 | Derivative | Stock Option (right to buy) | 2025-07-09 | M | D | 455,282 | $0.00 | 622,809 | D | $0.68 · — to 2025-08-21 | 455,282 Common Stock | (F5) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days. |
| 5 | Derivative | Stock Option (right to buy) | 2025-07-09 | M | D | 40,000 | $0.00 | 20,369 | D | $5.28 · — to 2027-03-07 | 40,000 Common Stock | (F6) 25% of the shares subject to the option will vest on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter. |